Furthermore, previous findings revealed that mortalin enhances the resistance of cancer cells to complement-dependent cytotoxicity (CDC) and can, thus, promote tumor escape and attenuate immunotherapy efficacy [18]. This evidence concerns the gene HSPA9 and cancer.